Sweden
· Delayed Price · Currency is SEK · Price in NOKGenetic Analysis AS Statistics
Total Valuation
Genetic Analysis AS has a market cap or net worth of SEK 25.53 million. The enterprise value is 22.95 million.
| Market Cap | 25.53M |
| Enterprise Value | 22.95M |
Important Dates
The last earnings date was Friday, November 1, 2024.
| Earnings Date | Nov 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Genetic Analysis AS has 49.38 million shares outstanding. The number of shares has increased by 126.87% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 49.38M |
| Shares Change (YoY) | +126.87% |
| Shares Change (QoQ) | +17.14% |
| Owned by Insiders (%) | 8.42% |
| Owned by Institutions (%) | 12.75% |
| Float | 21.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.49 |
| PB Ratio | 1.09 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.16 |
| EV / Sales | 1.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.45 |
Financial Position
The company has a current ratio of 2.26, with a Debt / Equity ratio of 0.38.
| Current Ratio | 2.26 |
| Quick Ratio | 2.10 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.54 |
| Interest Coverage | -28.05 |
Financial Efficiency
Return on equity (ROE) is -80.72% and return on invested capital (ROIC) is -38.38%.
| Return on Equity (ROE) | -80.72% |
| Return on Assets (ROA) | -29.76% |
| Return on Capital (ROIC) | -38.38% |
| Revenue Per Employee | 904,082 |
| Profits Per Employee | -940,744 |
| Employee Count | 21 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 2.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.56% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -36.56% |
| 50-Day Moving Average | 0.70 |
| 200-Day Moving Average | 0.74 |
| Relative Strength Index (RSI) | 31.07 |
| Average Volume (20 Days) | 41,516 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genetic Analysis AS had revenue of SEK 18.99 million and -19.76 million in losses. Loss per share was -0.38.
| Revenue | 18.99M |
| Gross Profit | 15.44M |
| Operating Income | -19.39M |
| Pretax Income | -19.76M |
| Net Income | -19.76M |
| EBITDA | -19.61M |
| EBIT | -19.39M |
| Loss Per Share | -0.38 |
Balance Sheet
The company has 10.98 million in cash and 8.50 million in debt, giving a net cash position of 2.48 million or 0.05 per share.
| Cash & Cash Equivalents | 10.98M |
| Total Debt | 8.50M |
| Net Cash | 2.48M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 22.56M |
| Book Value Per Share | 0.46 |
| Working Capital | 11.37M |
Cash Flow
In the last 12 months, operating cash flow was -15.84 million and capital expenditures 660, giving a free cash flow of -15.84 million.
| Operating Cash Flow | -15.84M |
| Capital Expenditures | 660 |
| Free Cash Flow | -15.84M |
| FCF Per Share | -0.32 |
Margins
Gross margin is 81.35%, with operating and profit margins of -102.13% and -104.06%.
| Gross Margin | 81.35% |
| Operating Margin | -102.13% |
| Pretax Margin | -104.06% |
| Profit Margin | -104.06% |
| EBITDA Margin | -103.29% |
| EBIT Margin | -102.13% |
| FCF Margin | -83.42% |
Dividends & Yields
Genetic Analysis AS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -126.87% |
| Shareholder Yield | -126.87% |
| Earnings Yield | -73.62% |
| FCF Yield | -62.04% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |